The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes

Launched by VEJLE HOSPITAL · Feb 23, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new imaging technique called dermal-Optical Coherence Tomography (D-OCT) to help doctors accurately identify a type of skin cancer known as Basal Cell Carcinoma (BCC) around the eyes. The study aims to determine how effective this imaging method is in diagnosing BCC in the eye area compared to its effectiveness in other parts of the body. The researchers hope to find out if using a special probe makes the imaging even better and if the results from this imaging can be as reliable as traditional skin biopsies.

To participate in the trial, individuals must be at least 18 years old and have BCC that doctors suspect is located around the eyes. They should be able to understand and communicate in Danish, and they need to be willing to provide informed consent. Participants will undergo imaging scans and may also have skin biopsies to confirm the diagnosis. It's important to know that those with certain conditions, like significant scarring or those unwilling to have a biopsy, will not be eligible for this study. Overall, this trial aims to improve the way doctors diagnose skin cancer around the eyes, potentially leading to better treatment outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically suspected periocular BCC.
• • Biopsy-verified BCC
• • Clinically suspected relapse of periocular BCC
• • Age more than 18 years at baseline.
• • Legally competent, able to give verbal and written consent
• • Communicate in Danish verbally as well as in writing
• • Willingness to participate and able to give informed consent and can comply with protocol requirements.
• Exclusion Criteria:
• • Anatomical circumstances that make OCT-scanning impossible, i.e., extensive scarring of eyelids, or large ulcerating crusts that hampers scanning
• • Unwillingness to undergo a skin biopsy or excision of lesion.
• • Inability to sign informed consent.